Aktienanalyse zu Illumina Inc (ILMN)ILMNIllumina Inc

Illumina, Inc. specializes in DNA sequencing and array-based technologies, serving customers in research, clinical and applied markets. The Company's products are used for applications in the life sciences, oncology, reproductive health, agriculture, and other emerging segments. Its customers include genomic research centers, academic institutions, government laboratories, and hospitals, as well as pharmaceutical, biotechnology, commercial molecular diagnostic laboratories, and consumer genomics companies. Its comprehensive line of products addresses the scale of experimentation and breadth of functional analysis to advance disease research, drug development, and the development of molecular tests. It also specializes in data-driven proteomics technology. Its products include instruments, kits and reagents, selection tools, and software and analysis. Its services include sequencing services, microarray services, proactive instrument monitoring, and instrument services and training. It operates in the Healthcare sector (LABORATORY ANALYTICAL INSTRUMENTS industry).

Illumina Inc is currently a hold. The stock is priced at $215.59, with a forward P/E ratio of 42.02, indicating high future earnings expectations. However, insider selling has surged by 17343.19%, which raises concerns about management's confidence in the stock's near-term performance. The RSI is at 52.77, suggesting the stock is neither overbought nor oversold, indicating a wait-and-see approach is prudent.

18 analysts cover ILMN: 11 rate it Buy, 6 Hold and 1 Sell. The average price target is 133.54.